CoChat

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Background: Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) have proven effective but have serious side effects. Ondansetron, also a 5-HT3RA, has been widely used as an antiemetic with an excellent safety record for over two decades. Our aim was to assess its effectiveness in IBS-D. Methods: 120 patients meeting Rome III criteria for IBS-D entered a randomised, double-blind, placebo-controlled crossover study of 5 weeks of ondansetron 4 mg versus placebo with dose titration allowed, up to two tablets three times daily in the first 3 weeks. Patients completed daily diaries documenting stool consistency using the Bristol Stool Form score. Gut transit was measured in the last week of each treatment. The primary endpoint was average stool consistency in the last 2 weeks of treatment. Results: Ondansetron significantly improved stool consistency (mean difference in stool form between ondansetron and placebo −0.9, 95% CI −1.1 to −0.6, p<0.001). Compared with placebo, patients on ondansetron experienced fewer days with urgency (p<0.001), lower urgency scores (p<0.001), reduced frequency of defaecation (p=0.002) and less bloating (p=0.002), although pain scores did not change significantly. IBS symptom severity score fell more with ondansetron than placebo (83±9.8 vs 37±9.7, p=0.001). 65% reported adequate relief with ondansetron but not placebo compared with 14% reporting relief with placebo but not ondansetron, relative risk 4.7, 95% CI 2.6 to 8.5, p<0.001. Conclusions: Ondansetron relieves some of the most intrusive symptoms of IBS-D, namely loose stools, frequency and urgency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2013-305989

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design. This shows the two 5-week treatment periods during which subjects were randomised to either ondansetron or placebo. Week 1 was for baseline assessment, Each 5-week treatment period allowed dose adjustment until weeks 4 and 5 when no further dose adjustment or rescue medication was allowed. Symptoms on weeks 4 and 5 provided the clinical endpoints. Symptoms were assessed throughout the study and during the washout period to ensure symptoms had returned to baseline before starting the next treatment. Frequent visits and telephone contact ensured protocol compliance.
Figure 1 Study design. This shows the two 5-week treatment periods during which subjects were randomised to either ondansetron or placebo. Week 1 was for baseline assessment, Each 5-week treatment period allowed dose adjustment until weeks 4 and 5 when no further dose adjustment or rescue medication was allowed. Symptoms on weeks 4 and 5 provided the clinical endpoints. Symptoms were assessed throughout the study and during the washout period to ensure symptoms had returned to baseline before starting the next treatment. Frequent visits and telephone contact ensured protocol compliance.CC BY · PubMed Central
Figure 2 Consort diagram showing patient flow with dropouts and protocol violations. CRP, C-reactive protein.
Figure 2 Consort diagram showing patient flow with dropouts and protocol violations. CRP, C-reactive protein.CC BY · PubMed Central
Figure 3 Time course for stool consistency during the two treatment periods. Time shown in weeks. Washout period was variable so the value during the last 7 days is shown as the first data point in the treatment period 2. The graph shows very little placebo effect with rapid onset of treatment effect on commencing ondansetron and loss of effect on discontinuing.
Figure 3 Time course for stool consistency during the two treatment periods. Time shown in weeks. Washout period was variable so the value during the last 7 days is shown as the first data point in the treatment period 2. The graph shows very little placebo effect with rapid onset of treatment effect on commencing ondansetron and loss of effect on discontinuing.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 39 references

Research works printed but not linked: 1

  1. 10.1111/j.1572-0241.2002.07111.x · doi:10.1111/j.1572-0241.2002.07111.x · Paper page

Cited by

See all 273

Metadata

Authors
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R.
Affiliations
  • NIHR Nottingham Digestive Diseases Biomedical Research Unit (GB)
  • Nottingham Digestive Diseases Biomedical Research Unit, Queens Medical Centre, Nottingham, UK
  • Wythenshawe Hospital (GB)
  • University of Nottingham (GB)
Venue
Gut
Publisher
BMJ
Published
2013-12-12
Volume
63
Issue
10
Pages
1617-1625
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2129997920
Cited by
246
References
39
Citations by year
2026: 10 · 2025: 24 · 2024: 16 · 2023: 18 · 2022: 19 · 2021: 24 · 2020: 22 · 2019: 17 · 2018: 20 · 2017: 22 · 2016: 26 · 2015: 16 · 2014: 11
FWCI
16.66
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Gut (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, other-oa)
  • Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • HighWire Press Open Archive (submittedVersion)
Funders
National Institute for Health and Care Research (PB-PG-0107-12127)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Keywords
ondansetron, irritable bowel syndrome with diarrhea, 5-HT3 receptor antagonists, stool consistency, bowel urgency, bloating, symptom severity
MeSH terms
Adult, Diarrhea, Double-Blind Method, Feces, Female, Humans, Male, Middle Aged, Serotonin Antagonists, Treatment Outcome, Ondansetron, Cross-Over Studies, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. https://app.cochat.ai/papers/10.1136/gutjnl-2013-305989
The paper
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014). A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. https://doi.org/10.1136/gutjnl-2013-305989

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.